Product image of Linezolid Olikla (Linezolid) supplied by GNH India

Linezolid Olikla

Active Ingredient:
Linezolid
Origin:
EU

Linezolid Olikla (Linezolid)

Linezolid, the active ingredient in Linezolid Olikla, is an oxazolidinone presented as an intravenous formulation for injection use. It treats serious bacterial infections such as skin and soft‑tissue infections, community‑acquired and hospital‑acquired pneumonia, and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) in adult patients.

GNH India supplies Linezolid Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for clinical use across multiple regions.

Manufacturer / TM Owner

Olikla S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linezolid is an oxazolidinone antibiotic used for several serious bacterial infections.

  • Skin and soft tissue infections: effective against Gram‑positive pathogens, including MRSA, reducing lesion size and bacterial load.
  • Community‑acquired pneumonia: provides coverage for atypical and resistant organisms, improving respiratory function.
  • Hospital‑acquired pneumonia: treats resistant strains in intensive‑care settings, aiding recovery.
  • MRSA infections: active against methicillin‑resistant Staphylococcus aureus, facilitating infection control.

How It Works

  • Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex and thereby halting translation. This action is bacteriostatic against most organisms and bactericidal against certain strains, leading to suppression of bacterial growth without affecting human ribosomal function.

Side Effects

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Nausea: transient gastrointestinal upset.
  • Diarrhea: loose stools, usually mild.
  • Headache: occasional mild to moderate pain.
  • Metallic taste: temporary alteration in taste perception.
  • Rash: mild skin erythema.

Serious or Rare Side Effects

  • Thrombocytopenia: significant drop in platelet count.
  • Peripheral neuropathy: sensory disturbances, tingling or numbness.
  • Serotonin syndrome: risk when combined with serotonergic agents.
  • Lactic acidosis: rare metabolic disturbance.
  • Optic neuropathy: visual changes requiring prompt evaluation.

Precautions & Warnings

When using Linezolid, clinicians should observe several safety measures.

  • Monitor blood counts: watch for thrombocytopenia and anemia.
  • Assess renal function: adjust therapy in severe impairment.
  • Avoid serotonergic drugs: risk of serotonin syndrome.
  • Use cautiously in hepatic disease: potential for increased exposure.
  • Review concomitant medications: consider interactions with MAO inhibitors.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Linezolid interacts with several drug classes that may alter safety or efficacy.

Major Interactions (Avoid)

  • MAO inhibitors: can precipitate hypertensive crisis.
  • Serotonergic agents (SSRIs, SNRIs, tramadol): risk of serotonin syndrome.
  • Rifampin: induces metabolism, reducing linezolid exposure.

Moderate Interactions (Monitor Closely)

  • Warfarin: may enhance anticoagulant effect, monitor INR.
  • NSAIDs: increased bleeding risk with thrombocytopenia.
  • Antacids containing aluminum or magnesium: may affect absorption, separate dosing times.

Frequently Asked Questions

Linezolid Olikla is indicated for serious bacterial infections such as skin and soft‑tissue infections, community‑acquired pneumonia, hospital‑acquired pneumonia, and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA). It is prescribed for adult patients when these pathogens are identified or strongly suspected.

Linezolid blocks bacterial protein synthesis by binding to the 50S ribosomal subunit. This prevents the formation of the initiation complex needed for translation, halting bacterial growth. The action is bacteriostatic for most organisms and bactericidal for certain strains, providing effective control of resistant Gram‑positive bacteria.

The dosing regimen for Linezolid Olikla is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals set the appropriate dose and duration for each individual case.

The safety of Linezolid Olikla in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Linezolid Olikla, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Linezolid offers oral and intravenous options and is effective against MRSA strains resistant to many beta‑lactams and glycopeptides. Compared with vancomycin, linezolid provides better lung penetration and does not require therapeutic drug monitoring, though it carries a distinct safety profile that must be considered.

Linezolid Olikla should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions preserves the stability and potency of the intravenous formulation.

Linezolid Olikla is supplied as an intravenous solution and is administered by slow infusion into a vein, typically over 30‑60 minutes. The exact infusion rate and duration are determined by the prescribing clinician based on patient condition and institutional protocols.

Serious risks include thrombocytopenia, peripheral neuropathy, optic neuropathy, serotonin syndrome when combined with serotonergic drugs, and rare cases of lactic acidosis. Patients should be monitored regularly for blood‑count changes, neurological symptoms, and any signs of serotonin excess.

Linezolid Olikla is contraindicated in patients with known hypersensitivity to linezolid or any component of the formulation. It should also be avoided in individuals currently taking monoamine oxidase inhibitors or other serotonergic agents due to the risk of severe drug interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linezolid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT